<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>28(1)</volume><submitter>Andrews N</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>This study is to evaluate the effects of darbepoetin alfa (darbe) on neutrophil count in preterm neonates treated for anemia of prematurity.&lt;h4>Methods&lt;/h4>This was a retrospective chart review comparing the absolute neutrophil counts (ANCs) of neonates administered 2 doses of subcutaneous darbe 10 mcg/kg to that of a randomly selected comparator group of neonates not administered the drug. Neonates &lt;34 weeks gestational age, gestational age between 23w1d and 33w4d, born between July 2016 and June 2019, were included in the study.&lt;h4>Results&lt;/h4>The ANCs of 45 darbe-treated neonates compared with those of 45 randomly selected comparator control neonates revealed no difference in the rate of occurrence of neutropenia (ANC ≤1000/μL) between the darbe-treated neonates (26.7%</pubmed_abstract><journal>The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG</journal><pagination>41-47</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9901317</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Characterization of Neutropenia in Preterm Neonates Following Administration of Darbepoetin Alfa.</pubmed_title><pmcid>PMC9901317</pmcid><pubmed_authors>Friedman S</pubmed_authors><pubmed_authors>Dunham M</pubmed_authors><pubmed_authors>Andrews N</pubmed_authors><pubmed_authors>Dean R</pubmed_authors><pubmed_authors>Chabra S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Characterization of Neutropenia in Preterm Neonates Following Administration of Darbepoetin Alfa.</name><description>&lt;h4>Objective&lt;/h4>This study is to evaluate the effects of darbepoetin alfa (darbe) on neutrophil count in preterm neonates treated for anemia of prematurity.&lt;h4>Methods&lt;/h4>This was a retrospective chart review comparing the absolute neutrophil counts (ANCs) of neonates administered 2 doses of subcutaneous darbe 10 mcg/kg to that of a randomly selected comparator group of neonates not administered the drug. Neonates &lt;34 weeks gestational age, gestational age between 23w1d and 33w4d, born between July 2016 and June 2019, were included in the study.&lt;h4>Results&lt;/h4>The ANCs of 45 darbe-treated neonates compared with those of 45 randomly selected comparator control neonates revealed no difference in the rate of occurrence of neutropenia (ANC ≤1000/μL) between the darbe-treated neonates (26.7%</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2025-04-25T19:19:07.86Z</modification><creation>2025-04-06T07:57:46.05Z</creation></dates><accession>S-EPMC9901317</accession><cross_references><pubmed>36777988</pubmed><doi>10.5863/1551-6776-28.1.41</doi></cross_references></HashMap>